Clovis Oncology Announces Proposed Secondary Offering of Shares of Common
Stock by Selling Stockholders
*No new shares of common stock being sold by the Company
BOULDER, Colo. -- December 2, 2013
Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that certain selling
stockholders have commenced an underwritten public offering of 2,000,000
shares of the Company’s common stock which they recently acquired as
consideration in connection with the Company’s acquisition of EOS (Ethical
Oncology Science) S.p.A.
All net proceeds from the sale of the common stock will be received by the
selling stockholders. The Company will not receive any of the proceeds, and
the total number of shares of its outstanding common stock will not change as
a result of the offering.
J. P. Morgan Securities LLC is acting as the sole manager for the offering. In
addition, the selling stockholders intend to grant J. P. Morgan Securities LLC
a 30-day option to purchase up to an additional 15 percent of the number of
shares sold to cover over-allotments, if any. The offering is subject to
market conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the offering.
This offering is being made only by means of a prospectus and related
prospectus supplement, copies of which may be obtained from J. P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or by calling toll-free (866) 803-9204.
The shares are being offered by the selling stockholders pursuant to an
effective shelf registration statement. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring,
developing and commercializing innovative anti-cancer agents in the U.S.,
Europe and additional international markets. Clovis Oncology targets
development programs at specific subsets of cancer populations, and
simultaneously develops diagnostic tools that direct a compound in development
to the population that is most likely to benefit from its use. Clovis Oncology
is headquartered in Boulder, Colorado, and has additional offices in San
Francisco, California and Cambridge, UK.
Clovis Oncology, Inc.
Anna Sussman, 303-625-5022
Breanna Burkart, 303-625-5023
Press spacebar to pause and continue. Press esc to stop.